肾性贫血的发病机制及治疗现状

李 欣然¹, 林 晓龙¹, 王 玉浔²
1、华北理工大学附属医院肾内科 河北唐山 063000
2、通讯作者华北理工大学附属医院肾内科 河北唐山 063000

摘要

摘要：慢性肾脏病(chronic kidney disease，CKD)是目前我国乃至全球均高发的慢性病之一，其常见的并发症：肾性贫血，对 CKD 患者的生
活质量和远期预后均有着重要影响，因此提高 CKD 患者生存率，改善其长期预后的重点之一就是肾性贫血有效治疗。目前肾性贫血的常见
的治疗药物有红细胞生成刺激剂和铁剂，近些年随着人们对肾性贫血发病机制的研究逐渐深入，不断涌现出很多新的治疗方式及药物。

关键词

关键词：慢性肾脏病；肾性贫血；发病机制；治疗

参考

[1] 汤曦,石运莹,王俭勤,陆晨,周竹,查艳,付荣国,王利华,王彩丽,

周晓玲,杜晓刚,王婷立,段棣飞,付平.中国成人慢性肾脏病及其并发

症早期筛查临床路径专家建议（2023 版）[J].中国实用内科杂

志,2023,43(03):198-205.DOI:10.19538/j.nk2023030105.

[2] 中国输血协会临床输血学专业委员会《血液成分输注临床

路径》制订协作组血液成分输注临床路径专家共识（2018 年）[J].

临床血液学杂志,2018,31(2):81-84.

[3] 李宏彬，梁军，马强. 罗沙司他胶囊与重组人促红素治疗肾

性贫血的效果及预后比较[J]. 中国医药导报，2020,017(008):178-81.

[4] Noonan ML,Ni P,Agoro R, et al. The HIF-PHI BAY85-3934

(Molidustat) I-mproves Anemia and Is Associated With Reduced Levels

of Circulating F-GF23 in a CKD Mouse Model[J].J Bone Miner

Res,2021,36(6):1117-1130.

[5] Sinha SD, Bandi VK, Bheemareddy BR, et al. Efficacy,

tolerability and s-afety of darbepoetin alfa injection for the treatment of

anemia associated with chronic kidney disease (CKD) undergoing dialysis:

a randomized, phase-Ⅲ trial[J]. BMC Nephrol, 2019, 20(1): 90. DOI:

10.1186/s12882-019-1209-1.

[6] Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly

subcutaneou-s C. E. R. A. maintains stable hemoglobin control in

patients with chronic kidney disease on dialysis and converted directly

from epoetin one to three times weekly[J]. Clin J Am Soc Nephrol, 2007,

2(4):637-646. DOI: 10.2215/CJN.03631006.

[7] BEGUM S,LATUNDE-DADA G O. Anemia of inflammation

withan emph-asis on chronic kidney disease [J]. Nutrients,2019,11(10):

2424.

[8] 刘旭, 尹道馨, 代文迪, 等.评价慢性肾脏病患者贫血治疗

的血红蛋白靶目标值的临床研究[J]. 临床和实验医学杂志,2014,

(19):1572-1575. DOI: 10.3969/j.issn.1671-4695.2014.19.002.

[9] Locatelli F, Bárány P, Covic A, et al. Kidney disease:

improving global o-utcomes guidelines on anaemia management in

chronic kidney disease: a European renal best practice position

statement[J]. Nephrol Dial Transplant, 2013, 28(6): 1346-1359. DOI:

10.1093/ndt/gft033.

[10] Min Hyang Ki,Sung Su Ah,Oh Yun Kyu,Kim Yeong

Hoon,Chung Wooky-ung,Park Sue K,Ahn Curie,Lee Sung Woo. Hepcidin,

iron indices and bon-e mineral metabolism in non-dialysis chronic

kidney disease.[J]. Nephrolog-y, dialysis, transplantation : official

publication of the European Dialysis a-nd Transplant Association -

European Renal Association,2020,35(1).

[11] Haase V H. Hypoxia-inducible factor-prolyl hydroxylase

inhibitors in the t r-eatment of anemia of chronic kidney disease[J].

Kidney Int Suppl (201 1), 2021,11(1);8-25.

[12] QIE S,JIAO N,DUAN K,et al. The efficacy and safety of

roxa-dustat treatment for anemia in patients with kidney disease: a

meta-analysis and systematic review[J]. Int Urol Nephrol,2021,10:1007-

1020.